Uber isn’t required to report its finances publicly, but the privately held company has decided to forgo that luxury for the first time.

Uber said its revenue growth is outpacing losses, hoping to show the business is on a strong trajectory as it attempts to address a recent cascade of scandals.

The ride-hailing giant more than doubled gross bookings in 2016 to $20 billion, according to financial information Uber shared with Bloomberg. Net revenue was $6.5 billion, while adjusted net losses were $2.8 billion, excluding the China business, which it sold last summer.

Uber declined to report first-quarter numbers, saying they were in line with expectations but that the company hasn’t yet presented them to investors.

In recent months, Uber has seen an exodus of top executives as it investigates claims of sexual harassment and a toxic work culture.

Uber’s business is massive and getting bigger. In the last three months of 2016, gross bookings increased 28 percent from the previous quarter to $6.9 billion. The company generated $2.9 billion in revenue, a 74 percent increase from the third quarter. Losses rose 6.1 percent over the same period to $991 million.

You’ve got 4 days to file your taxes

Hey, procrastinators: Don’t freak out if you haven’t finished your taxes. The IRS is giving you until Tuesday.

The usual April 15 deadline falls on Saturday this year. That would normally push the deadline to Monday. However, Monday is a holiday in the District of Columbia, so by law, the filing deadline is extended until Tuesday.

Monday is Emancipation Day in the District of Columbia. It marks the day in 1862 in which 3,100 slaves living in Washington were freed.

All the states that usually have an April 15 deadline have delayed their filing date as well. A handful of states have later deadlines.

Taxpayers can request an automatic six-month extension.

FDA rejects Lilly’s arthritis drug

Eli Lilly said U.S. regulators have rejected its much-anticipated pill for rheumatoid arthritis, the drugmaker’s second drug development setback since November.

The Food and Drug Administration said in a letter to the company that it needed more information about the drug’s safety and the best doses, Lilly said Friday in a statement.

Lilly said it disagrees with FDA’s conclusions but will work with the agency on a plan to eventually get the drug, baracitinib, approved for U.S. patients.

In November, Lilly’s experimental medicine solanezumab flopped in a closely watched test in patients with mild Alzheimer’s disease.